Transfusions and risk of failure in childhood acute lymphoblastic leukemia

Andrew Freiberg, Michael L. Hancock, Keith D. Kunkel, Gaston K. Rivera, William M. Crist

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

To examine the relationship of blood product support to treatment outcome in childhood ALL, we reviewed records of all 358 patients with newly diagnosed ALL treated on St Jude Total Therapy Study XI (February 1984 to September 1988). All but six patients received blood products (median 7 units, range 0-246), with approximately 90% given during the 6-week induction period. Because all 16 patients who received ≥ 50 units failed, the number of units transfused was predictive of treatment failure in multivariate analysis (relative risk = 1.8, p = 0.02), although the number of units transfused was also associated with initial leukocyte count and age. Among the remaining 342 patients who received < 50 units, the number of units transfused was associated with reduced event-free survival in univariate analysis only, with maximal significance at > 7 units (p = 0.006). Because exclusion of the 16 patients who received the most blood eliminates the independent effect of transfusions on patient outcome, we believe that the number of transfusions is largely an epiphenomenon which reflects the effects of two risk factors not included in traditional outcome analysis in childhood ALL. These are acuity of illness during induction, and reduction of chemotherapy doses during induction therapy, due to the severity of illness. Immunomodulation caused by exposure to blood products appears unlikely to contribute strongly to outcome in childhood ALL.

Original languageEnglish (US)
Pages (from-to)1220-1223
Number of pages4
JournalLeukemia
Volume8
Issue number7
StatePublished - Jul 1994

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Induction Chemotherapy
Immunomodulation
Treatment Failure
Leukocyte Count
Multivariate Analysis
Therapeutics

All Science Journal Classification (ASJC) codes

  • Hematology
  • Cancer Research

Cite this

Freiberg, A., Hancock, M. L., Kunkel, K. D., Rivera, G. K., & Crist, W. M. (1994). Transfusions and risk of failure in childhood acute lymphoblastic leukemia. Leukemia, 8(7), 1220-1223.
Freiberg, Andrew ; Hancock, Michael L. ; Kunkel, Keith D. ; Rivera, Gaston K. ; Crist, William M. / Transfusions and risk of failure in childhood acute lymphoblastic leukemia. In: Leukemia. 1994 ; Vol. 8, No. 7. pp. 1220-1223.
@article{dd06e94330bc48a4b41b3eeaf585cade,
title = "Transfusions and risk of failure in childhood acute lymphoblastic leukemia",
abstract = "To examine the relationship of blood product support to treatment outcome in childhood ALL, we reviewed records of all 358 patients with newly diagnosed ALL treated on St Jude Total Therapy Study XI (February 1984 to September 1988). All but six patients received blood products (median 7 units, range 0-246), with approximately 90{\%} given during the 6-week induction period. Because all 16 patients who received ≥ 50 units failed, the number of units transfused was predictive of treatment failure in multivariate analysis (relative risk = 1.8, p = 0.02), although the number of units transfused was also associated with initial leukocyte count and age. Among the remaining 342 patients who received < 50 units, the number of units transfused was associated with reduced event-free survival in univariate analysis only, with maximal significance at > 7 units (p = 0.006). Because exclusion of the 16 patients who received the most blood eliminates the independent effect of transfusions on patient outcome, we believe that the number of transfusions is largely an epiphenomenon which reflects the effects of two risk factors not included in traditional outcome analysis in childhood ALL. These are acuity of illness during induction, and reduction of chemotherapy doses during induction therapy, due to the severity of illness. Immunomodulation caused by exposure to blood products appears unlikely to contribute strongly to outcome in childhood ALL.",
author = "Andrew Freiberg and Hancock, {Michael L.} and Kunkel, {Keith D.} and Rivera, {Gaston K.} and Crist, {William M.}",
year = "1994",
month = "7",
language = "English (US)",
volume = "8",
pages = "1220--1223",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "7",

}

Freiberg, A, Hancock, ML, Kunkel, KD, Rivera, GK & Crist, WM 1994, 'Transfusions and risk of failure in childhood acute lymphoblastic leukemia', Leukemia, vol. 8, no. 7, pp. 1220-1223.

Transfusions and risk of failure in childhood acute lymphoblastic leukemia. / Freiberg, Andrew; Hancock, Michael L.; Kunkel, Keith D.; Rivera, Gaston K.; Crist, William M.

In: Leukemia, Vol. 8, No. 7, 07.1994, p. 1220-1223.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Transfusions and risk of failure in childhood acute lymphoblastic leukemia

AU - Freiberg, Andrew

AU - Hancock, Michael L.

AU - Kunkel, Keith D.

AU - Rivera, Gaston K.

AU - Crist, William M.

PY - 1994/7

Y1 - 1994/7

N2 - To examine the relationship of blood product support to treatment outcome in childhood ALL, we reviewed records of all 358 patients with newly diagnosed ALL treated on St Jude Total Therapy Study XI (February 1984 to September 1988). All but six patients received blood products (median 7 units, range 0-246), with approximately 90% given during the 6-week induction period. Because all 16 patients who received ≥ 50 units failed, the number of units transfused was predictive of treatment failure in multivariate analysis (relative risk = 1.8, p = 0.02), although the number of units transfused was also associated with initial leukocyte count and age. Among the remaining 342 patients who received < 50 units, the number of units transfused was associated with reduced event-free survival in univariate analysis only, with maximal significance at > 7 units (p = 0.006). Because exclusion of the 16 patients who received the most blood eliminates the independent effect of transfusions on patient outcome, we believe that the number of transfusions is largely an epiphenomenon which reflects the effects of two risk factors not included in traditional outcome analysis in childhood ALL. These are acuity of illness during induction, and reduction of chemotherapy doses during induction therapy, due to the severity of illness. Immunomodulation caused by exposure to blood products appears unlikely to contribute strongly to outcome in childhood ALL.

AB - To examine the relationship of blood product support to treatment outcome in childhood ALL, we reviewed records of all 358 patients with newly diagnosed ALL treated on St Jude Total Therapy Study XI (February 1984 to September 1988). All but six patients received blood products (median 7 units, range 0-246), with approximately 90% given during the 6-week induction period. Because all 16 patients who received ≥ 50 units failed, the number of units transfused was predictive of treatment failure in multivariate analysis (relative risk = 1.8, p = 0.02), although the number of units transfused was also associated with initial leukocyte count and age. Among the remaining 342 patients who received < 50 units, the number of units transfused was associated with reduced event-free survival in univariate analysis only, with maximal significance at > 7 units (p = 0.006). Because exclusion of the 16 patients who received the most blood eliminates the independent effect of transfusions on patient outcome, we believe that the number of transfusions is largely an epiphenomenon which reflects the effects of two risk factors not included in traditional outcome analysis in childhood ALL. These are acuity of illness during induction, and reduction of chemotherapy doses during induction therapy, due to the severity of illness. Immunomodulation caused by exposure to blood products appears unlikely to contribute strongly to outcome in childhood ALL.

UR - http://www.scopus.com/inward/record.url?scp=0028283987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028283987&partnerID=8YFLogxK

M3 - Article

C2 - 8035615

AN - SCOPUS:0028283987

VL - 8

SP - 1220

EP - 1223

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 7

ER -

Freiberg A, Hancock ML, Kunkel KD, Rivera GK, Crist WM. Transfusions and risk of failure in childhood acute lymphoblastic leukemia. Leukemia. 1994 Jul;8(7):1220-1223.